Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
19.94
-0.16 (-0.80%)
At close: Mar 28, 2025, 4:00 PM
20.54
+0.60 (3.02%)
After-hours: Mar 28, 2025, 5:30 PM EDT
Castle Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Castle Biosciences stock have an average target of 40, with a low estimate of 36 and a high estimate of 44. The average target predicts an increase of 100.60% from the current stock price of 19.94.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 28, 2025.
Analyst Ratings
The average analyst rating for Castle Biosciences stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 2 | 2 | 2 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $36 → $37 | Buy | Maintains | $36 → $37 | +85.56% | Feb 28, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $41 | Buy | Reiterates | $41 | +105.62% | Jan 2, 2025 |
| Scotiabank | Scotiabank | Buy Maintains $37 → $44 | Buy | Maintains | $37 → $44 | +120.66% | Nov 6, 2024 |
| Lake Street | Lake Street | Strong Buy Maintains $34 → $40 | Strong Buy | Maintains | $34 → $40 | +100.60% | Nov 5, 2024 |
| Keybanc | Keybanc | Buy Maintains $28 → $36 | Buy | Maintains | $28 → $36 | +80.54% | Nov 5, 2024 |
Financial Forecast
Revenue This Year
292.58M
from 332.07M
Decreased by -11.89%
Revenue Next Year
310.16M
from 292.58M
Increased by 6.01%
EPS This Year
-1.57
from 0.62
EPS Next Year
-1.80
from -1.57
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 329.9M | 365.4M | 345.0M | ||
| Avg | 292.6M | 310.2M | 326.0M | ||
| Low | 255.7M | 269.9M | 302.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.7% | 24.9% | 11.2% | ||
| Avg | -11.9% | 6.0% | 5.1% | ||
| Low | -23.0% | -7.8% | -2.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.14 | -1.07 | -1.11 | ||
| Avg | -1.57 | -1.80 | -1.70 | ||
| Low | -1.85 | -2.57 | -2.22 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.